PSA Screening: The Numbers Behind a Decision Nobody Will Make For You

The prostate-specific antigen test is the only cancer screening test in American practice that official guidance explicitly declines to recommend for or against. Not because the evidence is missing — there is a great deal of it — but because the evidence shows the benefits and harms are close enough in size that reasonable men, given the same numbers, make opposite decisions.

What the grades mean

The Task Force grades reflect the size and certainty of net benefit, not whether a test detects anything. PSA detects plenty. The question is whether detecting it leaves men better off.

A Grade C is not a shrug. It is a specific statement: on average across a population the net benefit is small, and therefore the individual’s own weighting of the outcomes should decide it. Two men who value “avoid dying of prostate cancer” and “avoid becoming impotent and incontinent for a cancer that would never have troubled me” differently should rationally choose differently.

The Grade D at 70 is a firmer statement. Prostate cancer usually grows slowly; the harms of finding and treating it are immediate. Past 70, and particularly with other health conditions in the picture, the arithmetic stops working.

The thousand-men table

Here is what the Task Force’s own evidence review projects for 1,000 men aged 55 to 69 screened over roughly 13 years, compared with 1,000 not screened.

Two rows deserve emphasis.

The first is the last one. Screening has not been shown to reduce all-cause mortality. It reduces deaths attributed to prostate cancer, by a small amount, and that reduction is not large enough to detect in total deaths. Any test that involves biopsies and major surgery has its own mortality, and it eats into the benefit.

The second is 50 men with sexual dysfunction against 1.3 deaths prevented. That ratio is the entire argument, and it is why the recommendation is a conversation rather than a schedule.

Overdiagnosis, explained properly

Overdiagnosis is the most misunderstood word in cancer screening. It does not mean a false positive, and it does not mean a mistake. It means finding a real cancer, correctly, that would never have caused symptoms or shortened the man’s life.

Prostate cancer is unusually prone to this. Autopsy studies of men who died of unrelated causes routinely find prostate cancer nobody knew about. Many of these tumours grow so slowly that the man’s other causes of death arrive first.

The problem is that once found, a cancer is very hard to leave alone — for the patient, and for the doctor. Between 20% and 50% of screen-detected prostate cancers fall into this category. Those men gain nothing from the diagnosis and are exposed to everything that follows it.

This is why the harms column is so heavily populated. The men who become incontinent are not victims of bad surgery. Many of them are victims of good surgery for a cancer that did not need it.

What the treatment trial showed

The ProtecT trial is the strongest evidence available on what to do after a screen-detected diagnosis, and it changes how the harms above should be read.

It randomised 1,643 men aged 50 to 69 with localised, screen-detected prostate cancer to three arms: active monitoring (545), radical prostatectomy (553) and radical radiotherapy (545). At fifteen years, about 97% of men in every arm were alive — no significant difference in prostate cancer mortality between monitoring and radical treatment.

Monitoring did carry more progression and metastasis. It did not carry more death. And roughly a quarter of the men assigned to monitoring had still had no invasive treatment at all after fifteen years.

The implication is important. The 50 men with sexual dysfunction in the screening table are not an unavoidable consequence of screening. They are a consequence of treating. If the men who are diagnosed go onto active surveillance rather than straight to surgery, a large part of the harm column shrinks — without, on this evidence, costing lives.

What has changed since the grade was set

The current recommendation dates from 2018, and the pathway has moved since. Three changes matter, and all of them push in the same direction.

MRI before biopsy. Rather than biopsying everyone with a raised PSA, multiparametric MRI is now widely used first, biopsying only suspicious lesions and targeting the needle at them. This reduces biopsies, reduces detection of clinically insignificant disease, and improves detection of the significant kind.

Active surveillance as default for low-risk disease. The share of American men with low-risk prostate cancer managed by surveillance rather than immediate treatment has risen enormously. ProtecT is a large part of why.

Better use of the PSA number itself. Free-to-total PSA ratio, PSA density and velocity, and newer risk calculators all reduce the number of men sent to biopsy on a single borderline reading.

None of this is captured in a table built on trials that ran through the 2000s. The benefit column is probably similar; the harm column, in a system using MRI-first and surveillance, is smaller than the historic figures. That is a reason to ask specifically about the pathway your urologist uses — not a reason to assume the harms have gone.

Who should weight it differently

The Task Force recommendation applies to average-risk men. Three groups are not average, and the argument for screening — and for starting earlier, around 40 to 45 — is stronger for them:

• Black men. Incidence is substantially higher and mortality roughly double that of white men in the United States. They were also underrepresented in the screening trials the recommendation rests on, which means the estimates above are least reliable for the group with most at stake.
• A father or brother with prostate cancer, particularly diagnosed young — roughly a doubling of risk, more with several relatives.
• Known BRCA1 or BRCA2 mutations, or a strong family history of breast, ovarian or pancreatic cancer. BRCA2 in particular raises both risk and aggressiveness.

Symptoms are a separate matter entirely. Trouble urinating, blood in urine or semen, or new bone pain are reasons to be investigated, not screened. Screening is for men with no symptoms; that is what the word means. Most urinary symptoms in older men turn out to be benign prostatic enlargement, which is common and not cancer — but that determination is made by a doctor, not by you.

How to make the decision

If you are 55 to 69, the questions that actually settle it:

• How would you feel about a diagnosis you might not need? Some men find a known, monitored cancer manageable. Others find it intolerable and will want it removed, which is precisely how a harmless tumour becomes an incontinence problem. Knowing which man you are is genuinely decision-relevant.
• Would you accept active surveillance if low-risk cancer were found? If yes, the harms shrink considerably. If no, you should count them at full weight.
• Does the clinic use MRI before biopsy? Ask before the PSA, not after.
• What is your life expectancy? Benefit takes ten to fifteen years to appear. Below that horizon, only the harms are in reach.
• Are you in one of the higher-risk groups above?

What is not a good reason to decide either way is a poster in a waiting room, a campaign in November, or a friend’s anecdote. A man who says screening saved his life may well be one of the 100 diagnosed rather than the 1.3 saved, and there is no way for him — or for you — to tell which.

PSA screening is the one item on the men’s screening list where the correct answer genuinely depends on you. Everything else on that list is closer to a straightforward yes.

This article is for information only and is not medical advice. It cannot account for your individual circumstances. Talk to a doctor about your own situation, particularly before starting or stopping any prescription medication.